Molecular Target definition

Molecular Target means [***].
Sample 1Sample 2Sample 3
Molecular Target means a molecule shown in an assay specified by the RMC to play a role in a research pathway in human tumor cells.
Sample 1Sample 2Sample 3
Molecular Target means any cDNA, peptide or protein identified in the Research Program.
Sample 1Sample 2Sample 3

Examples of Molecular Target in a sentence

  • Pfizer may, in its sole, unfettered discretion, select for HTS during the Research Program and the three (3) year period immediately following the Research Period, any Molecular Target identified in the Research Program.

  • Pfizer shall be obligated to make each payment only once with respect to each Licensed Product affected by an Event and such payment for such Event shall not be due with respect to any subsequent Licensed Product directed to a Molecular Target and indication which has previously been the subject of the same Event.

  • The following shall become Rigel Technology, and Rigel shall have no obligations to Pfizer with respect to: Molecular Targets which are not selected pursuant to Section 2.6.3; and any Molecular Target for which Pfizer has failed to satisfy the due diligence obligations set forth in Section 2.6.3; PROVIDED, HOWEVER, that no Molecular Target for which Pfizer has initiated HTS shall revert to Rigel.

  • To prevent the reversion of a Molecular Target to Rigel pursuant to Section 2.6.5, Pfizer must commence HTS on a Molecular Target within a period of two (2) years after its selection of such Molecular Target for HTS.

  • Mammalian Target of Rapamycin, a Molecular Target in Squamous Cell Carcinomas of the Head and Neck.

  • Transcription Factor STAT3 as a Novel Molecular Target for Cancer Prevention.

  • The KEAP1-NRF2 System as a Molecular Target of Cancer Treatment.Cancers (Basel) 2020, 13, doi:10.3390/cancers13010046.

  • If, in the unlikely event, Pfizer determines in its absolute, unfettered discretion to commercialize an unpatented product, it will meet with Rigel to discuss additional compensation, if any, to Rigel, for use of the Molecular Target on the basis of which Pfizer conducted HTS to identify such product given Pfizer's advancement and commercialization of an unpatented product will have involved extraordinary development costs to Pfizer.

  • A Molecular Target for Cancer Chemotherapy (with Memorial Sloax-Xxxxxxxxx Xxxcer Center); Funding Period: 21 September 1995 to 31 August 2000.

  • P38 MAP Kinase: Molecular Target for the Inhibition of Pro-inflammatory Cytokines.


More Definitions of Molecular Target

Molecular Target means any Antigen to which a Mab binds.
Sample 1Sample 2Sample 3
Molecular Target means one of the specific proposed molecular targets that both parties agree to include in the collaborative Research Program.
Sample 1

Related to Molecular Target

  • KPI Target means the acceptable performance level for a KPI as set out in each KPI;

  • Collaboration Target means the Initial Collaboration Targets set forth on Exhibit F and any Additional Target or Substitute Target that is selected in accordance with Section 3.3 of this Agreement.

  • Soft Target means a target that will suffer minimum damage and cause minimum damage to the subject vehicle in the event of a collision.

  • Lead Compound means any compound of lead other than galena which, when treated in the manner described below, yields to an aqueous solution of hydrochloric acid a quantity soluble lead compound exceeding, when calculated as lead monoxide, five percent of the dry weight of the portion taken analysis.

  • Bioassay means the determination of kinds, quantities or concentrations and, in some cases, the locations of radioactive material in the human body, whether by direct measurement, in vivo counting, or by analysis and evaluation of materials excreted or removed from the human body. For purposes of these rules, “radiobioassay” is an equivalent term.

  • Collaboration Compound means any of the following: (a) FG-4592, (b) any HIF Compound (other than FG-4592) that is added to this Agreement pursuant to Section 3.6, and (c) any salts, esters, complexes, chelates, crystalline and amorphous morphic forms, pegylated forms, enantiomers (excluding regioisomers), prodrugs, solvates, metabolites and catabolites of any of the foregoing ((a) or (b)).

  • BMS means the Company, all related companies, affiliates, subsidiaries, parents, successors, assigns and all organizations acquired by the foregoing.

  • Novartis shall have the meaning set forth in the Preamble.

  • Development Milestone is defined in Section 5.3.

  • ISIS means the department’s individualized services information system.

  • DS Electric generation service that is provided at retail pursuant to the Applicable Legal Authorities under the Company’s retail electric tariffs and under any other agreements or arrangements between the Company and Customers, to any Customer that is not being served by an EGS. Default Allocation Assessment – shall have the meaning ascribed to it under the PJM Agreements. Delivery Period – The delivery period specified in an Appendix C Transaction Confirmation. Delivery Point – Means the applicable zone of the Company as designated by PJM. DS Customer(s) – Retail customers who are provided Default Service pursuant to the terms of this Agreement, the Applicable Legal Authorities and the Company’s retail tariffs.

  • GSK has the meaning set forth in the preamble.

  • Development Milestone Event has the meaning set forth in Section 7.2.1.

  • Merck has the meaning set forth in the preamble.

  • Antibody means a molecule comprising or containing one or more immunoglobulin variable domains or any fragments, derivatives, variants or modifications thereof that bind to the same antigen.

  • Licensed Compound means [***].

  • Biomarker means a parameter or characteristic in a patient or Patient Sample, the measurement of which is useful (a) for purposes of selecting appropriate therapies or patient populations or monitoring disease susceptibility, severity or state, or monitoring therapies for such patient and/or (b) for predicting the outcome of a particular treatment of such patient.

  • Research Program Term has the meaning set forth in Section 2.2.

  • Development Milestone Payment shall have the meaning set forth in Section 9.2(a).

  • Clinical laboratory means a facility for the microbiological, serological, chemical, hematological, radiobioassay, cytological, immunohematological, pathological, or other examination of materials derived from the human body for the purpose of providing information for the diagnosis, prevention, or treatment of a disease or assessment of a medical condition.

  • Collaborative drug therapy management means participation by an authorized pharmacist and a physician in the management of drug therapy pursuant to a written community practice protocol or a written hospital practice protocol.

  • Research Plan shall have the meaning set forth in Section 2.1.

  • Product Candidate means any pharmaceutical product developed, manufactured and/or tested by or on behalf of the Company that has not received a Regulatory Authorization for commercial distribution other than in connection with pre-clinical or clinical trials.

  • Development Candidate means a Compound that meets the Development Candidate Criteria for the initiation of a Development Program for the treatment of CF, and which is the subject of a notice from Vertex to CFFT that Vertex intends to commence formal pre-clinical development of the Compound in the Field pursuant to the provisions of Section 3.1 hereof.

  • Participating Clinical Laboratory means a Clinical Laboratory which has a written agreement with the Claim Administrator or another Blue Cross and/or Blue Shield Plan to provide services to you at the time services are rendered.

  • Phase I Clinical Trial means a human clinical trial that is intended to initially evaluate the safety and/or pharmacological effect of a Product in subjects or that would otherwise satisfy requirements of 21 C.F.R. 312.21(a), or its foreign equivalent.